Nora Chávez Hdz

Clinical oncologist

[Nora Chávez Hdz @norachavezh]

#prodige24 mFOLFIRINOX better than gem as adjuvant treatment for #PancreaticCancer . Great job by the canadians!

[Nora Chávez Hdz @norachavezh]

woman 87 yo, w/out comorbidities, #breastcarcinoma micropapillary T4a N2, in mammography, suspicious contralateral lymph node. no other tumors. awaiting immunohistochemistry. what do you think? #oncologists

[Pathology mcqs @Pathology_mcqs]

Algorithm for MSI testing #pathtwitter #MSItesting #colorectal #uterine #braf #mlh1 #msh2 #msh6 #germline #lynch #sporadic

[Dr. Cathy Eng @CathyEngMD]

Excellent discussion from @KristenCiombor! 👏👏Great summary of the unanswered questions that remain #immunotherapy #colorectal #cancer @ASCO #ASCO24 @VUMCDiscoveries @VUMC_Cancer

[Dr. Cathy Eng @CathyEngMD]

Opening up the #CRC oral TransMet abstract session @asco #asco24: The potential role for #livertransplant in met #colorectal #cancer as presented by Dr. Rene Adam. 5yr OS = 57% vs 13%. 3 yr PFS = 33% vs 4% #crcsm @OncoAlert @FightCRC

[Dr. Cathy Eng @CathyEngMD]

NEOPRISM evaluated the role of Pembro in MSI-H/dMMR stage 2/3 #colorectal #cancer if TMB-H
👉🏻 Primary = pCR
👉🏻Path CR in 59% TMB-H pts.
#cancer #cancerresearch #ASCO24 @ASCO

[Dr. Cathy Eng @CathyEngMD]

Day #2 Excellent 👏👏overview re: IO Therapy in MSI-S #colorectal #cancer and the promise but remaining challenges: @myESMO #esmoambassadors #ESMOGI24 with Keynote speaker @MyriamChalabi #immunotherapy #cancer #cancerresearch

[Dr. Cathy Eng @CathyEngMD]

Plenary @asco #asco24 with Perioperative ESOPAC of FLOT vs CROSS for #esophageal #adenocarcinoma
🔵 median F/U 55M
🔵pCR = 16.8% vs 10%
🔵 3 yr OS = 57.4% vs 50%, HR= 0.70
🔵 3 yr PFS = 51.6% vs 35%, HR = 0.66
👉🏻 *New standard of care
#colorectal #cancer @asco #asco24 @ASCO #cancerresearch

[Nora Chávez Hdz @norachavezh]

@BourlonMaite @TheLancet @ConquerCancerFd @ASCO @jrgralow @INCMNSZ_DirInv @INCMNSZ_Ensena @incmnszmx @INCMNSZ_Uronco @aminnsz @Martin_AngelMD @nataliagandur @DrYukselUrun @yekeduz_emre @TomFlaigMD @oncodaily @TresUramigas @montypal @crisbergerot @OphiraG Congratulations!

[Arndt Vogel @ArndtVogel]

🔥hot off the press: Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment & follow-up
@Annals_Oncology
https://t.co/ShCkFPKNSH
👉we provide comprehensive recommendations for #PDAC
👏excellent team effort!
🙏thanks to T. Conroy & @DucreuxMichel
@myESMO @OncoAlert

[Journal of Clinical Oncology @JCO_ASCO]

🧐 In elderly patients w/ RAS/BRAF w/ metastatic #ColorectalCancer, panitumumab + FU/LV achieved similar progression-free & overall survival but better safety profile than panitumumab + FOLFOX ➡️ https://t.co/Wr5uDTm2Dy #CRCSM #gerionc @sara_lonardi1

[Arndt Vogel @ArndtVogel]

🔥Just out: The ESMO #GastricCancer Living Guideline
👉get the latest news & updates for daily decision making
@myESMO @OncoAlert

[Mark Lewis, MD, FASCO @marklewismd]

Being discussed this morning at @btfoundation Best of ASCO, a proposed flowchart to rectal cancer management in the wake of #ASCO23, PROSPECT, & PRODIGE 23 -- critique welcome! #medtwitter #crcsm

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

I promised I’d share some of the graphics so, #MondayMorning feels like the right time to dive in with these cool pictographs of HER2-treatment-related adverse events ⚠️

[Arndt Vogel @ArndtVogel]

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in HER2+ #CRC
@NatureComms
https://t.co/QV0ldJbWPg
👉ORR 45.3%, mPFS 6.9, mOS 15.5 and DoR 7.0 mo in IHC 3+/IHC 2+,ISH+
👉Pneumonitis 9.3%, TEAEs ≥3 65%
👉sig. activity independent of prior 🎯💊
@myESMO @OncoAlert

[Arndt Vogel @ArndtVogel]

A Critical Reappraisal of an Optimal TNT Strategy by an MDT: A Medical Oncologist’s Viewpoint
👏Excellent discussion by @JDekervel at #WCGIC2023
👇The Leuven Rectal Cancer Protocol for the MTD discussion
@myESMO @WCGIC @OncoAlert

[Arndt Vogel @ArndtVogel]

Checkpoint Inhibitors in MSI-H Colorectal Cancer at #WCGIC2023
👉excellent overview by @KristenCiombor
👉Test in every stage!
👉We need predictive biomarker
👉current evidence & ongoing studies such as ATOMIC, NEOPRISM-CRC, EA2201
@WCGIC @myESMO @OncoAlert

[Arndt Vogel @ArndtVogel]

Molecular Therapies in Pancreatic Ductal Adenocarcinoma: NGS for All or None - PRO by Philip Phillips at #WCGIC2023
👉search for the rare 🎯💊 in #PancreaticCancer
@myesmo @OncoAlert @WCGIC

[Ilana Schlam @IlanaSchlam]

Post #ASCO23 - Where are we with adjuvant CDK4/6 inhibitors? Summary of the available data, so far only abema approved, longer f/u is needed for OS, different CDK, patient populations and treatments #BSCM @OncoAlert

[Mariette Labots @DrMarietteLabo]

@ArndtVogel @TheLancetOncol @myESMO Folfoxiri- B (for R sided, braf/ras mt) 1.6 months > PFS compared with folfox/folfiri-b, yet with significantly more gr 3-4 neutropenia and diarrhea; more sae's and 7 TR- deaths..🤕

[Arndt Vogel @ArndtVogel]

🔥First-line systemic treatment strategies in patients with initially unresectable #CRC liver metastases (CAIRO5)
@TheLancetOncol
https://t.co/8Ij0c9UAba
🏅right-sided, mRAS or mBRAF CRC: FOLFOXIRI + Beva
🏅left-sided, RAS & BRAF WT CRC: FOLFOX/FOLFIRI + Beva or Pani
@myESMO @OncoAlert